Influenza virus vectors and uses therefor
Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant M2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. The mutant viruses disclosed herein including a mutant M2 sequence are also useful to deliver antigens to a subject, e.g., to induce an immune response to the antigen. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.
1. An immunogenic composition comprising the nucleic acid sequence of SEQ ID NO:35, wherein SEQ ID NO:35 further comprises a nucleic acid sequence encoding one or more antigens.
2. The immunogenic composition of claim 1 , further comprising part or all of SEQ ID NO:36.
3. The immunogenic composition of claim 1 , wherein the one or more antigens comprises an amino acid sequence derived from a pathogen or a tumor.
4. The immunogenic composition of claim 3 , wherein the pathogen comprises a virus, bacteria, fungus, protozoan, multi-cellular parasite, or prion.
5. A method for propagating a recombinant influenza virus, comprising: contacting a host cell with a recombinant influenza virus comprising the nucleic acid sequence of claim 1 , incubating the host cell for a sufficient time and under conditions suitable for viral replication, and isolating progeny virus particles.
6. The method of claim 5 , wherein the recombinant influenza virus further comprises part or all of SEQ ID NO:36.
7. The method of claim 5 , wherein the one or more antigens comprises an amino acid sequence derived from a pathogen or a tumor.
8. The method of claim 7 , wherein the pathogen comprises a virus, bacteria, fungus, protozoan, multi-cellular parasite, or prion.
9. A method of preparing a vaccine, comprising: placing a host cell in a bioreactor; contacting the host cell with a recombinant virus comprising the nucleic acid sequence of claim 1 , incubating the host cell for a sufficient time and under conditions suitable for viral propagation; isolating the progeny virus particles; and
formulating the progeny virus particles for administration as a vaccine.
10. The method of claim 9 , wherein the nucleic acid sequence further comprises part or all of SEQ ID NO: 36.
11. The method of claim 9 , wherein the one or more antigens comprises an amino acid sequence derived from a pathogen or a tumor.
12. The method of claim 11 , wherein the pathogen comprises a virus, bacteria, fungus, protozoan, multi-cellular parasite, or prion.